Syndax pharmaceuticals inc (SNDX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-15,236

-14,000

-12,829

-14,916

-14,302

-18,837

-17,339

-18,387

-19,398

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-12,971

-

-14,969

-8,358

-10,330

-5,263

-7,731

-6,214

-4,911

Adjustments to reconcile net loss to net cash from operating activities:
Depreciation

23

-

-

-

-180

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization and accretion of investments

110

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash operating lease expense

108

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

62

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation, amortization and accretion

-

-

-

-

-

-

-145

-75

-62

-

154

73

6

-

-69

4

53

-

190

171

96

Stock-based compensation

1,829

1,525

1,550

1,338

1,592

1,472

1,737

1,571

1,421

1,280

1,345

1,448

1,377

947

792

779

2,190

1,170

1,288

1,100

324

Change in fair value of warrants and derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1,720

-

-

-

-

Other

-

-

-

-

-

-12

-1

3

-1

0

0

-1

-7

-

-

-

-

-

-

-

-

Change in fair value of warrants and derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

137

Changes in operating assets and liabilities:
Prepaid expenses and other assets

2,530

-10

-2,603

212

2,453

-3,817

-63

225

2,622

81

-834

-59

1,141

1,549

-314

-219

613

486

265

110

344

Accounts payable

2,820

-454

4,355

-2,070

2,908

-1,740

-2,119

2,709

358

12

-1,006

434

366

365

612

349

-403

615

80

-228

578

Deferred revenue

-379

-379

-380

-379

-379

-379

-380

-379

-379

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-305

-

-305

-305

-305

-305

-305

-17

17,287

Accrued expenses and other liabilities

-2,512

548

-3,881

3,939

-4,017

810

-287

-360

811

1,297

3,886

129

-7

958

2,177

422

1,285

-716

-54

952

-2,122

Net cash used in operating activities

-15,925

-12,727

-8,529

-12,525

-16,831

-15,043

-18,469

-15,149

-19,870

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-12,668

-

-11,448

-6,890

-6,403

-4,295

-5,182

-3,996

11,045

Purchases of property and equipment

-

-

-

-

-

14

0

0

173

-

-

-

-

0

55

73

133

-

-

-

-

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

-

-

-

-

Purchases of short-term investments

34,938

35,126

8,998

39,266

20,628

18,703

25,992

22,466

11,683

39,251

25,023

73,908

14,081

26,567

21,820

31,069

78,863

33,286

26,684

20,474

21,564

Proceeds from sales and maturities of short-term investments

15,885

41,722

21,362

20,335

33,380

34,679

29,500

41,750

24,500

40,843

31,985

37,352

25,095

47,895

30,025

30,520

31,857

15,877

19,284

3,265

2,080

Net cash (used in) provided by investing activities

-19,053

6,596

12,364

-18,931

12,752

15,962

3,508

19,284

12,644

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock in initial public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-29

-141

-1,231

53,549

-

-

-

-

Proceeds from debt agreement, net

19,730

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Employee Stock Purchase Plan

64

57

53

45

27

69

32

63

34

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

11,014

-

8,050

-624

-47,137

-17,558

-7,413

-17,214

-19,484

Proceeds from stock option exercises

338

-

-

-

-

-

-

-

-

1

7

151

118

-

-

-

-

-

-

-

-

Principal payments on capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

60,945

18,665

7,713

Other

-

-

-

-

-2

17

-8

0

-1

-

-1

0

-1

-1

-1

-1

-1

-

-

-

-

Net cash provided by financing activities

54,998

58

80

6

28,426

6,145

9,462

89

33

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

117

-

1,710

-1,232

53,548

-9,182

60,060

18,677

7,712

NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

20,020

-6,073

3,915

-31,450

24,347

7,064

-5,499

4,224

-7,193

14,442

-2,257

631

-1,537

-

-

-

-

-

-

-

-

NET INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,688

-8,746

8

-31,035

47,465

-2,533

-727

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest

126

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

203

SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance costs debt included in accounts payable and accrued expenses

82

-

-

-

171

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment purchases included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22

73

-

-

-

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,412

Accretion of dividends on convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,598

-

-

-

1,749

Issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

26

135

-

-141

-1,230

1,400

-

-

-

-

IPO issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

Vesting of restricted stock

-

-

-

-

-

-

-

-

-

-

0

48

11

-

10

11

10

-

-

-

-

Reclassification of common stock warrant liability to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4,551

-

-

-

-

Conversion of preferred stock to common stock upon closing of initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1

328,942

-

-

-

-

At-the-Market Offering [Member]
Proceeds from issuance of common stock, net

-

0

0

0

830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Private Placement [Member]
Proceeds from issuance of common stock, net

34,866

1

0

-192

27,571

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-